Showing 2661-2670 of 7592 results for "".
- Dupilumab Reduces Inflammatory Biomarkers in Pediatric AD: Studyhttps://practicaldermatology.com/news/dupilumab-reduces-inflammatory-biomarkers-pediatric-ad/2467953/Dupilumab significantly reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis (AD), according to results from recent phase 3 trials. Pediatric patients treated with dupilumab demonstrated substantial reductions in key serum biomarkers associated w
- European Commission Approves Celltrion’s Stelara Biosimilar SteQeymahttps://practicaldermatology.com/news/european-commission-approves-celltrions-stelara-biosimilar-steqeyma/2467952/Celltrion announced that the European Commission (EC) has approved SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases, including psoriasis. The EC's approval follows a positive opinion from the Committee for Medici
- Higher BMI in Early Childhood Linked with Increased Atopic Dermatitis Riskhttps://practicaldermatology.com/news/higher-bmi-early-childhood-linked-increased-atopic-dermatitis-risk/2467912/New research indicates that a higher body mass index (BMI) in early childhood is associated with an increased risk of developing immune-mediated skin diseases (IMSDs) such as atopic dermatitis (AD), alopecia areata (AA), and psoriasis. The research team looked at data on over 2 million chi
- Panel IDs Key Skincare Strategies for Adult Acnehttps://practicaldermatology.com/news/dermatologists-identify-key-skincare-strategies-adult-acne/2467834/New research featuring input from an expert acne panel emphasized the critical importance of skin care in managing adult acne. The panel, consisting of eight dermatologists, looked at the role of skin barrier function in adult acne and the benefits of adjunctive skin care, such as cleanse
- Survey: Mixed Sentiments for AI in Dermatologyhttps://practicaldermatology.com/news/ai-dermatology-survey-reveals-mixed-sentiments/2467817/A national survey of U.S. dermatologists reveals both enthusiasm and concern about the potential integration of artificial intelligence chatbots (AIC) into dermatological practice. The study, published in the Journal of Drugs in Dermatology, evaluated results from an online cross-sectiona
- New Plasma Proteins Linked to Atopic Dermatitis Riskhttps://practicaldermatology.com/news/new-plasma-proteins-linked-atopic-dermatitis-risk/2467771/New research has identified eight plasma proteins associated with atopic dermatitis (AD), potentially opening new avenues for treatment. Publishing in the Archives of Dermatological Research, the study authors used summary-data-based Mendelian Randomization (SMR) and evaluated dat
- FDA Approves Nemluvio for Prurigo Nodularis Treatmenthttps://practicaldermatology.com/news/fda-approves-nemluvio-prurigo-nodularis-treatment/2467770/The U.S. Food and Drug Administration (FDA) has approved Galderma's Nemluvio® (nemolizumab) for the treatment of adults with prurigo nodularis, according to a news release. Nemolizumab, a monoclonal antibody IL-31 inhibitor, targets a neuroimmune cytokine implicated in prurigo nodularis p
- Dietary Sodium Intake Linked to Increased Atopic Dermatitis Riskhttps://practicaldermatology.com/news/dietary-sodium-intake-linked-increased-atopic-dermatitis-risk/2467760/Higher dietary sodium intake has been associated with an increased risk and severity of atopic dermatitis (AD), according to new research in JAMA Dermatology. Researchers for the cross-sectional analysis examined 215,832 participants aged 37-73 years from a UK Biobank cohort using 24-hour
- Annual Science of Skin Event Highlights Empowering Conversations About Chronic Diseaseshttps://practicaldermatology.com/news/annual-science-skin-event-highlights-empowering-conversations-about-chronic-diseases/2467751/Empowering conversations around chronic skin diseases is something AbbVie aims to normalize. The fourth annual Science of Skin event featured a panel of experts and patients who shared insights on managing chronic skin conditions and improving quality of life, and Practical Dermatology was there.
- Five-Year Study Validates Dupilumab for Atopic Dermatitis Managementhttps://practicaldermatology.com/news/five-year-study-validates-dupilumab-atopic-dermatitis-management/2467714/New research has provided evidence of benefit from a long-term strategy of dupilumab for the treatment of atopic dermatitis (AD). Researchers for the multicenter cohort study looked at clinical effectiveness, response times, and reasons for discontinuation of dupilumab treatment over a pe